Litifilimab Explained

Type:mab
Mab Type:mab
Source:o
Target:BDCA2
Cas Number:2407378-48-5
Pubchem:472406881

Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti-BDCA2 monocolonal antibody.[1] [2] [3]

Notes and References

  1. Web site: Litifilimab - Biogen . AdisInsight . Springer Nature Switzerland AG .
  2. Cho SK, Vazquez T, Werth VP . Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus . Expert Opinion on Investigational Drugs . 32 . 5 . 345–353 . May 2023 . 37148249 . 10.1080/13543784.2023.2212154 . 258547912 .
  3. Cho YM, Furie R . The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus . Immunotherapy . October 2023 . 37877249 . 10.2217/imt-2023-0086 . 264448220 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Litifilimab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.